GLP-1 Receptor Agonists Linked to Increased Risk of Gallbladder Disease in Large-Scale Safety Analysis
核心洞察
A comprehensive pharmacovigilance analysis of 1,651 patients found that GLP-1 receptor (搜索) agonists significantly increase the risk of cholecystitis (搜索) and cholelithiasis (搜索), with female patients showing 58.72% incidence compared to 37.07% in males.
The study revealed that liraglutide and semaglutide demonstrated the strongest safety signals for gallbladder complications, with reporting odds ratios of 6.75 and 5.74 respectively, while tirzepatide showed the shortest median onset time of 80 days.
Analysis of FDA adverse event data from 2004-2024 showed that 92.01% of gallbladder-related cases were classified as severe, with hospitalization required in nearly 50% of patients taking these diabetes and obesity (搜索) medications.
A comprehensive real-world safety analysis has revealed significant associations between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and gallbladder complications, raising important considerations for clinicians prescribing these increasingly popular diabetes and obesity (搜索) medications.
The pharmacovigilance study, published in Frontiers in Pharmacology, analyzed data from the FDA Adverse Event Reporting System (FAERS) database spanning from Q1 2004 to Q2 2024. Researchers identified 1,651 patients who experienced cholecystitis (搜索) and cholelithiasis (搜索) while taking GLP-1 RAs, generating 1,829 adverse event reports.
Gender and Age Disparities in Risk Profile
The analysis revealed striking demographic patterns in gallbladder complications. Female patients demonstrated a significantly higher incidence rate of 58.72% compared to 37.07% in male patients. The 45-64 age group emerged as the most vulnerable population, accounting for 33.84% of all cases.
"The overall rate of cholecystitis (搜索) and cholelithiasis (搜索) was notably higher in female patients than in male patients, suggesting the need for heightened caution when prescribing these drugs to female patients," the researchers noted.
Notably, dulaglutide showed different demographic patterns, with nearly equal male-to-female ratios and higher concentration in patients aged 65 years and older, representing 32.79% of cases in this age group.
Drug-Specific Safety Signals
The study employed three sophisticated data mining algorithms to detect safety signals across five commonly prescribed GLP-1 RAs. Liraglutide demonstrated the strongest association with gallbladder complications, showing a reporting odds ratio (ROR) of 6.75 with 95% confidence interval of 6.17-7.38. Semaglutide followed closely with an ROR of 5.74 (95% CI: 5.24-6.28).
Exenatide showed a more moderate association (ROR = 1.88, 95% CI = 1.72-2.05), while dulaglutide presented the weakest signal (ROR = 1.29, 95% CI = 1.12-1.49). Tirzepatide, despite having a relatively moderate ROR of 1.98, demonstrated the shortest median onset time of just 80 days.
Temporal Patterns and Clinical Implications
The overall median onset time for GLP-1 RA-induced cholecystitis (搜索) and cholelithiasis (搜索) was 182 days. However, significant variations emerged between different medications and patient demographics. Exenatide showed the longest median onset time at 230 days, while a considerable proportion of patients developed complications within seven days of initiating treatment.
Gender differences in onset times were particularly pronounced for certain medications. Female patients experienced notably longer onset times with exenatide and dulaglutide compared to males, with differences of 125 and 149 days respectively. Conversely, male patients showed longer onset times when using semaglutide and tirzepatide.
Severity and Clinical Outcomes
The severity of these adverse events proved concerning, with 92.01% of reports classified as serious. Hospitalization was required in 49.93% of cases, followed by other serious outcomes including life-threatening events and disability. The majority of reports (67.80%) originated from the United States, with healthcare professionals and consumers serving as the primary reporters.
Mechanistic Understanding
The researchers identified multiple mechanisms by which GLP-1 RAs may induce gallbladder complications. These medications can alter bile composition by increasing cholesterol secretion, elevating the bile cholesterol saturation index and promoting cholesterol stone formation. Rapid weight loss, a common effect of GLP-1 RA therapy, represents another significant risk factor.
"Rapid weight loss reduces the secretion of cholecystokinin, which diminishes gallbladder motility and delays gallbladder emptying, ultimately leading to the formation of cholesterol crystals and cholelithiasis (搜索)," the study authors explained.
Long-acting GLP-1 RAs such as semaglutide and dulaglutide may exert more pronounced inhibitory effects on gallbladder contraction due to their extended half-lives, potentially explaining their stronger safety signals compared to shorter-acting agents like exenatide.
Clinical Recommendations
The findings have immediate implications for clinical practice. The researchers recommend close monitoring for cholecystitis (搜索) and cholelithiasis (搜索) in high-risk populations, particularly older women receiving GLP-1 RA therapy. Patients presenting with upper abdominal pain, nausea, or vomiting should undergo prompt imaging evaluation, such as gallbladder ultrasound.
Extra caution is warranted for patients receiving higher doses, undergoing long-term treatment, or experiencing rapid weight loss, as these factors may further elevate risk. Healthcare providers should also consider gender differences when monitoring patients, as onset patterns vary significantly between male and female patients across different GLP-1 RAs.
The study's temporal analysis suggests that vigilance should be maintained throughout treatment duration, with particular attention during the first few months for tirzepatide users and extended monitoring for patients on exenatide, liraglutide, and semaglutide.
Study Limitations and Future Directions
The researchers acknowledged several limitations, including potential geographic and demographic biases in the FAERS database, with most reports originating from the United States. Differences in drug approval dates and clinical usage patterns may also influence reported case numbers.
The study authors emphasized that while pharmacovigilance databases are valuable for identifying statistical associations, they cannot establish causality or calculate absolute risk rates. They recommended integrating FAERS data with prescription databases and electronic health records to provide more comprehensive safety assessments in future research.